知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

9512 records (took 0.053 seconds)

筛选除外

    METHODS FOR TREATING NEUROBLASTOMA
    81.
    发明申请
    METHODS FOR TREATING NEUROBLASTOMA 有权

    公开(公告)号：US20210378999A1

    公开(公告)日：2021-12-09

    申请号：US17147697

    申请日：2021-01-13

    Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA ,  CANCER PREVENTION PHARMACEUTICALS, INC.

    Inventor： Eugene GERNER ,  Elizabeth BRUCKHEIMER

    IPC: A61K31/198 ,  A61K31/192 ,  A61K31/203 ,  A61K31/415 ,  A61K31/616 ,  A61K31/69 ,  A61K31/7048 ,  C12Q1/6886 ,  A61K45/06 ,  A61P35/00 ,  C07K16/30 ,  A61K39/395

    Abstract: The present invention provides methods and kits a) for preventing and/or treating neuroblastoma (e.g., high-risk neuroblastoma) that is linked, in part, to high levels of ODC activity and increased cellular polyamine content, b) for predicting cancer patient survival, especially cancer patients whose cancer is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and c) for selecting treatment options for such patients based on the allelic nucleotide sequence or SNP at positions +263 and/or +316 of the ODC1 gene. The invention also provides, cancer treatment methods comprising the determination of the ODC1 genotype at the +263 and/or +316 positions, as a means to guide treatment selection, which includes, in some aspects the administration of pharmaceutically effective amounts of α-difluoromethylornithine (DFMO), either as a monotherapy or in combination with one or more other drugs. In addition, the present invention provides methods for preventing and/or treating patients that have been determined to have cancer stem cells, such as patients in cancer remission that are at risk for relapse.

    COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS
    84.
    发明申请
    COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS 有权

    公开(公告)号：US20210346328A1

    公开(公告)日：2021-11-11

    申请号：US17278103

    申请日：2019-09-20

    Applicant: The Johns Hopkins University

    Inventor： Xu Cao

    IPC: A61K31/192 ,  A61K31/42 ,  A61K31/415 ,  A61K31/5415 ,  A61K31/616 ,  A61K31/407 ,  A61K31/405 ,  A61K31/12 ,  A61K31/196 ,  A61K31/18 ,  A61P19/02

    Abstract: Provided herein are methods of treating, delaying progression of, or reducing the severity of metabolic disorders characterized with increased COX-2 expression and/or PGE2 expression and/or EP4 expression in bone related cells through administration of an agent configured to inhibit and/or diminish COX-2 expression, and/or PGE2 expression, and/or EP4 expression in bone related cells. In some embodiments, such administration results in one or more of the following: inhibited or reduced COX-2 expression; inhibited or reduced PGE2 expression; inhibited or reduced EP4 expression; inhibited or reduced aberrant subchondral bone remodeling and/or innervation; inhibited or reduced cartilage degeneration; and inhibited or reduced joint destruction.

    STARCH-BASED RELEASE MODIFYING EXCIPIENTS AND PHARMACEUTICAL COMPOSITIONS DERIVED THEREFROM
    89.
    发明申请
    STARCH-BASED RELEASE MODIFYING EXCIPIENTS AND PHARMACEUTICAL COMPOSITIONS DERIVED THEREFROM 有权

    公开(公告)号：US20210299259A1

    公开(公告)日：2021-09-30

    申请号：US17345462

    申请日：2021-06-11

    Applicant: ALTUS FORMULATION INC.

    Inventor： Marc LEMIEUX ,  Bradut MITRASCA ,  Sonia GERVAIS ,  Damon SMITH

    IPC: A61K47/38 ,  A61K31/138 ,  A61K31/167 ,  A61K31/415 ,  A61K31/496

    Abstract: There is provide an extended release dosage form comprising a release modifying excipient comprising high amylose starch, cross-linked hydroxypropylated amylopectin, and a pre-gelatinized common starch; wherein the release modifying excipient is substantially free of crosslinks between amylose and amylopectin and substantially free of crosslinks between amylose and amylose. It has been found that the extended release properties of conventional cross-linked high amylose starches (e.g., Contramid®) can be reproduced by intimately mixing i) cross-linked chemically modified amylopectin; ii) a high amylose, non-chemically modified starch and; iii) a pre-gelatinized common starch. Producing a release modifying excipient in this way means that no chemical cross linking between (a) amylose and amylopectin or (b) amylose and amylose has occurred—properties heretofore considered vital for Contramid® function. The release modifying excipient blends overcome problems associated with use of Contramid, and provide a flexible platform for formulation of active pharmaceutical ingredients for controlled release applications.

Patent Agency Ranking